Strengthen CNS Trial Outcomes Through Smarter Data Capture

Florence (Flo) is an expert eCOA Scientist who has spent her career advising and guiding organizations on the electronic capture of clinical outcome assessments (COA) and the use of digital health technologies (DHTs) in clinical trials. She has a deep knowledge of clinical research, study design and leveraging technology to support it, having worked at the intersection between science and technology to navigate for better solutions.

Flo actively participates in industry consortia, regularly publishes and presents at international conferences. She uses her passionate and progressive mindset for driving positive change in the industry, focusing on optimizing clinical trial data capture to enhance the participant and site experience.

At uMotif, she provides scientific leadership across the organization, ensuring that the scientific voice is embedded across all functional areas to inform rigorous scientific practices.

Elan Cohen, PhD, a Licensed Psychologist in Pennsylvania and New Jersey, is a Principal Investigator at CenExel Marlton, New Jersey, a research site conducting inpatient and outpatient Phase I-IV CNS (psychiatry), early phase/translational medicine, use disorder, human abuse potential/liability and medically focused clinical trials. Since commencing work in the pharmaceutical industry in 2007, including within rater training and data surveillance companies, Dr. Cohen’s expertise includes developing clinical trial protocols, rater training programs, clinical data oversight paradigms and implementing systemic strategies aimed to reduce the placebo and nocebo effects. Dr. Cohen has presented at Investigators’ Meetings, industry conferences and published regarding empirically grounded participant retention strategies, psychometric rater distress and burnout and explorations of placebo and nocebo effect mitigations. Dr. Cohen has served on several pharmaceutical Advisory Boards and as lead Study Investigator for several clinical trials. He is also a member of the Cross-Company Abuse Liability Council.

Bruce brings his passion for advancing patient-centricity in clinical trials and technology to his work at uMotif. Bruce co-founded uMotif in 2012, initially inspired to help patients with Parkinson’s Disease track and better manage their condition. As Chief Patient Officer, he applies a patient-centric lens to guide the continued evolution of uMotif’s modern eCOA/ePRO solution and enable unrivaled engagement.

Bruce began his career working in clinical trials at British Biotech before joining the UK Civil Service Fast Stream in the Department for Culture, Media and Sport.

Enthusiastic about sharing his vision for expanding patient-centricity in clinical trial development and technology, Bruce speaks regularly at conferences, participates in academic research and working groups. He contributes frequently to publications, including Advanced Clinical Trials and Clinical Research News.

Anne-Marie Li-Kwai-Cheung is Chief Development Officer of Neurvati Neurosciences and GRIN Therapeutics. A Medicinal Chemist by training, she has more than 25 years of experience in pharmaceutical development, regulatory strategy and global product leadership. Prior to joining Neurvati, she served as Chief Development Officer at Wave Life Sciences and previously held senior leadership roles at Roche, where she led major neurology and rare disease programs including for Huntington’s disease and the global development for Multiple Sclerosis. Earlier in her career she held regulatory and development leadership roles at Genzyme. She is responsible for leading global development strategy and execution across the Neurvati and GRIN Therapeutics portfolio.